What is SpyBiotech?
Founded in 2017, SpyBiotech operates at the intersection of synthetic biology and immunology. The company utilizes a novel platform technology that enables the rapid development of vaccines by linking antigens to a protein-based delivery system. This modular approach allows for high-precision targeting, which is essential for addressing complex pathologies such as cancer and persistent infectious diseases. By maintaining a strategic partnership with the University of Oxford, the company benefits from a robust ecosystem of academic research and commercial translation, ensuring its technological edge remains sharp in a highly competitive global biotechnology landscape.
How much funding has SpyBiotech raised?
SpyBiotech has raised a total of $37.5M across 2 funding rounds:
Angel/Seed
$5M
Series A
$32.5M
Angel/Seed (2017): $5M with participation from GV and Oxford Sciences Innovation
Series A (2021): $32.5M led by GV, Future Fund, Oxford Sciences Innovation, and Braavos Investment Advisers
Key Investors in SpyBiotech
GV
GV is a prominent venture capital firm that invests across multiple stages and sectors, with a specific focus on life sciences and frontier technology innovations.
Oxford Sciences Innovation
Oxford Science Enterprises is an independent investment firm that builds transformational businesses through a unique partnership with the University of Oxford.
Future Fund
The Future Fund is an Australian sovereign wealth fund established to invest for the benefit of future generations and support long-term public sector financial stability.
What's next for SpyBiotech?
With the recent infusion of capital, SpyBiotech is well-positioned to scale its operational capacity and advance its lead candidates through human clinical trials. The strategic focus will likely center on expanding the versatility of its vaccine platform to address emerging global health threats and high-unmet-need oncology indications. As the company matures, investors will be monitoring the efficacy data from its ongoing trials, which will serve as a critical catalyst for future valuation growth and potential pharmaceutical partnerships. The firm's ability to maintain its research velocity while navigating the regulatory complexities of clinical-stage biotech will be the primary determinant of its long-term market success.
See full SpyBiotech company page
